Article
Study Compares Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients
A study published by the American Journal of Pharmacy Benefits compares dose escalation patterns of patients treated with TNF blockers.
A new study comparing the dose escalation patterns of rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab found that etanercept users were significantly less likely to have a dose escalation. The study, published by the American Journal of Pharmacy Benefits, notes that dose escalation is associated with higher drug treatment costs and greater risk of adverse events.
To read this American Journal of Pharmacy Benefits study in its entirety, follow this link.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
